Medication info
Danumet Tablet 50/500 mg

Danumet Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
K.S. Pharmaceutical Co., Ltd.
Appearance
Light pink oval film-coated tablet
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300830 · Approved 2023.03.13 · Insurance code 059001180

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2. Contraindications in Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions in Precautions for Use). Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Contraindications in Precautions for Use).

Ingredients

Manufacturer
K.S. Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medicine helps control blood sugar in patients with type 2 diabetes by using sitagliptin and metformin together. When used in conjunction with meal and exercise therapy, blood sugar control can be further enhanced. It is effective in helping patients manage their blood sugar and in treating diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received drug therapy for diabetes and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2. Contraindications in Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions in Precautions for Use). Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Contraindications in Precautions for Use).

Precautions

This medicine consists of two components and helps in controlling blood sugar. Firstly, the sitagliptin component can rarely cause serious allergic reactions, so if symptoms such as rash or difficulty breathing occur, the medication should be discontinued immediately. Additionally, there is a risk of pancreatitis, which is inflammation of the pancreas, so if there are any symptoms like abdominal pain, vomiting, or severe abdominal pain, consulting a doctor immediately is recommended. The metformin component can cause a rare but life-threatening condition known as lactic acidosis. This condition can present symptoms such as muscle pain, fatigue, difficulty breathing, and abdominal pain, so treatment should be sought immediately if these symptoms occur. This medicine should not be used in patients with moderate to severe renal impairment, severe infections, congestive heart failure, or acute myocardial infarction. It is also contraindicated in pregnant or breastfeeding women. While taking this medicine, renal function should be checked regularly, and if there is dehydration or severe vomiting or diarrhea, the medication should be temporarily discontinued and a doctor consulted. This medicine can cause hypoglycemia, particularly when taken with other hypoglycemic agents, so symptoms of hypoglycemia such as dizziness, sweating, and trembling should be monitored closely. It is advisable to avoid alcohol consumption during treatment with this medicine, and the medication should be temporarily discontinued prior to surgery or radiologic contrast studies. Lastly, some individuals may experience side effects such as diarrhea, headache, upper respiratory infections, so if these symptoms are severe, consulting a doctor is advisable.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 28 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • hypoglycemia
  • severe hypoglycemia
  • increased serum creatinine
  • elevated liver enzymes
  • rash
  • urticaria
  • cutaneous vasculitis
  • arthralgia with severe and disability
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • itching
  • dermatitis
  • anorexia
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly sealed container to protect it from air and moisture, and it is best to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the effectiveness of the drug for a longer duration.

Appearance and packaging

Appearance

Light pink oval film-coated tablet

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.